Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2013 financial results will be released on Thursday, May 2, at 4:05 p.m.

Gilead Sciences Inc disclosed that its Marketing Authorization Application for HCV sofosbuvir has been validated and is under review.

The market celebrated the first quarter results of Gilead Sciences, Inc.(NASDAQ:GILD) by sending the shares of the company to an all-time high on Friday.

loading. (RTTNews.com) - Gilead Sciences Inc. ( GILD ) will present at the 2013 UBS Global Healthcare Conference in ,New York City .

Gilead Sciences Inc. said Monday that the Food and Drug Administration rejected two marketing applications for HIV treatments, citing quality control problems at the company's manufacturing facilities.

(RTTNews.com) - Gilead Sciences Inc. ( GILD ) will present at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that detailed results from four Phase 3 clinical trials (NEUTRINO, FISSION, POSITRON and FUSION) evaluating sofosbuvir, the company's investigational once-daily nucleotide NS5B inhibitor for the ...

New York, NY -- (SBWIRE) -- 05/07/2013 -- Growing Stock Report expands its NASDAQ Decliners Weekly Watch List adding Gilead Sciences Inc. (NASDAQ:GILD), Express Scripts Holding Company (NASDAQ:ESRX), and Life Technologies Corporation ...

Affymax, Inc. (NASDAQ:AFFY) rose 14.17% to $1.45 on volume of 7.12M shares versus average-daily volume of 7.17M shares amid news that the biopharmaceutical equipment and technology assets at its Palo Alto, Calif.

Gilead Sciences, Inc. (NASDAQ:GILD) : By the end of last trading, Gilead Sciences, Inc. (NASDAQ:GILD) shares dropped US$0.05 (or 0.10%) to US$51.38 with about 9.68 million shares exchanged hands for the session, compared to its average volume of ...